Fesoterodine

From Wikipedia, the free encyclopedia - View original article

Fesoterodine
Systematic (IUPAC) name
[2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
Clinical data
Trade namesToviaz
AHFS/Drugs.commonograph
MedlinePlusa609021
Licence dataEMA:LinkUS FDA:link
Pregnancy cat.C (US)
Legal status Prescription only
RoutesOral
Pharmacokinetic data
Bioavailability52% (active metabolite)
Protein binding50% (active metabolite)
MetabolismHepatic (CYP2D6- and 3A4-mediated)
Half-life7–8 hours (active metabolite)
ExcretionRenal (70%) and fecal (7%)
Identifiers
CAS number286930-03-8 N
ATC codeG04BD11
PubChemCID 6918558
DrugBankDB06702
ChemSpider5293755 YesY
UNII621G617227 YesY
KEGGD07226 YesY
ChEMBLCHEMBL1201764 N
Chemical data
FormulaC26H37NO3 
Mol. mass411.278 g/mol
 N (what is this?)  (verify)
 
  (Redirected from Toviaz)
Jump to: navigation, search
Fesoterodine
Systematic (IUPAC) name
[2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
Clinical data
Trade namesToviaz
AHFS/Drugs.commonograph
MedlinePlusa609021
Licence dataEMA:LinkUS FDA:link
Pregnancy cat.C (US)
Legal status Prescription only
RoutesOral
Pharmacokinetic data
Bioavailability52% (active metabolite)
Protein binding50% (active metabolite)
MetabolismHepatic (CYP2D6- and 3A4-mediated)
Half-life7–8 hours (active metabolite)
ExcretionRenal (70%) and fecal (7%)
Identifiers
CAS number286930-03-8 N
ATC codeG04BD11
PubChemCID 6918558
DrugBankDB06702
ChemSpider5293755 YesY
UNII621G617227 YesY
KEGGD07226 YesY
ChEMBLCHEMBL1201764 N
Chemical data
FormulaC26H37NO3 
Mol. mass411.278 g/mol
 N (what is this?)  (verify)

Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).[1] It was approved by the European Medicines Agency in April 2007,[2] the US Food and Drug Administration on October 31, 2008 [3] and Health Canada on February 9, 2012.[4]

Fesoterodine is a prodrug. It is broken down into its active metabolite, 5-hydroxymethyl tolterodine, by plasma esterases.

Efficacy

References